<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACYCLOVIR- acyclovir sodium injection, solution </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<h1>Acyclovir Sodium Injection</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="c06190eb-14c9-441e-b519-44cb071e160e"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">FOR INTRAVENOUS INFUSION ONLY</span></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="a7601c4e-310e-4cdb-b1c8-017565380800"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Acyclovir Sodium Injection is a synthetic nucleoside analog, active against herpes viruses.  It is a sterile, aqueous solution for intravenous infusion, containing 50 mg acyclovir per mL in Water for Injection, USP.  The concentration is equivalent to 54.9 mg of acyclovir sodium per mL in Water for Injection, USP.  The sodium content is approximately 5.1 mg/mL.  The pH range of the solution is 10.85 to 11.50.  Further dilution of Acyclovir Sodium Injection in an appropriate intravenous solution must be performed before infusion (see <span class="Bold"><span class="Emphasis"><a href="#eb459c93-2afc-4f6b-9c78-c6db5a19cec5">DOSAGE AND ADMINISTRATION</a><a href="#eb459c93-2afc-4f6b-9c78-c6db5a19cec5">,</a><span class="Italics"><a href="#eb459c93-2afc-4f6b-9c78-c6db5a19cec5"> Administration</a></span></span></span>).</p>
<p>The chemical name of acyclovir sodium is 9-[(2-Hydroxyethoxy)methyl] guanine, and has the following structural formula:</p>
<p> </p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=badf347b-eeee-4239-9c74-966f262925aa&amp;name=acyclovir-sodium-injection-figure-1-fluor-str.jpg"> </p>
<p>Acyclovir sodium is a white, crystalline powder with the molecular formula C<span class="Sub">8</span>H<span class="Sub">10</span>N<span class="Sub">5</span>NaO<span class="Sub">3</span> and a molecular weight of 247.19.  The maximum solubility in water at 25°C exceeds 100 mg/mL.  At physiologic pH, acyclovir sodium exists as the unionized form with a molecular weight of 225 and a maximum solubility in water at 37°C of 2.5 mg/mL.  The pka’s of acyclovir are 2.27 and 9.25.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="bee8909d-5036-449d-8d6f-05212a90e108"></a><a name="section-3"></a><p></p>
<h1>VIROLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ce4082b4-cd37-4b2e-91f5-64c114f8117a"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Antiviral Action<br>
</h2>
<p class="First">Acyclovir is a synthetic purine nucleoside analogue with <span class="Italics"><span class="Emphasis">in vitro</span></span> and <span class="Italics"><span class="Emphasis">in vivo</span></span> inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2) and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>-zoster virus (VZV).</p>
<p>The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV.  This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue.  The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes.  <span class="Italics"><span class="Emphasis">In vitro</span></span>, acyclovir triphosphate stops replication of herpes viral DNA.  This is accomplished in three ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase.  The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the viral TK.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="aebea24c-5b51-4990-9686-2dfc1bf51afb"></a><a name="section-3.2"></a><p></p>
<h2>Antiviral Activities<br>
</h2>
<p class="First">The quantitative relationship between the <span class="Italics"><span class="Emphasis">in vitro</span></span> susceptibility of herpes viruses to antivirals and the clinical response to therapy has not been established in humans, and virus sensitivity testing has not been standardized.  Sensitivity testing results, expressed as the concentration of drug required to inhibit by 50% the growth of virus in cell culture (IC<span class="Sub">50</span>), vary greatly depending upon a number of factors.  Using plaque-reduction assays, the IC<span class="Sub">50</span> against herpes simplex virus isolates ranges from 0.02 to 13.5 mcg/mL for HSV-1 and from 0.01 to 9.9 mcg/mL for HSV-2.  The IC<span class="Sub">50</span> for acyclovir against most laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and clinical isolates of VZV ranges from 0.12 to 10.8 mcg/mL.  Acyclovir also demonstrates activity against the Oka vaccine <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of VZV with a mean IC<span class="Sub">50</span> of 1.35 mcg/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a236f164-fbf1-4d94-9df9-7c27ba860ab0"></a><a name="section-3.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span><br>
</h2>
<p class="First">Resistance of HSV and VZV to acyclovir can result from qualitative or quantitative changes in the viral TK and/or DNA polymerase.  Clinical isolates of HSV and VZV with reduced susceptibility to acyclovir have been recovered from immunocompromised patients, especially with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>.  While most of the acyclovir-resistant mutants isolated thus far from such patients have been found to be TK-deficient mutants, other mutants involving the viral TK gene (TK partial and TK altered) and DNA polymerase have been isolated.  TK-negative mutants may cause severe disease in infants and immunocompromised adults.  The possibility of viral resistance to acyclovir should be considered in patients who show poor clinical response during therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="b36b4953-81ac-4c85-b2d6-9d1af0c5188c"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="34090-1">
<a name="a13b4f65-814d-450a-8cdb-2e293112c2c8"></a><a name="section-4.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of acyclovir after intravenous administration have been evaluated in adult patients with normal renal function during Phase 1/2 studies after single doses ranging from 0.5 to 15 mg/kg and after multiple doses ranging from 2.5 to 15 mg/kg every 8 hours.  Proportionality between dose and plasma levels is seen after single doses or at steady-state after multiple dosing.  Average steady-state peak and trough concentrations from 1-hour infusions administered every 8 hours are given in Table 1.</p>
<br><p><span class="Bold"><span class="Emphasis">Table 1: Acyclovir Peak and Trough Concentrations <br>
                              at Steady-State</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">Dosage Regimen</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">C<span class="Sup">SS</span><span class="Sub">max</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">C<span class="Sup">SS</span><span class="Sub">trough</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">5 mg/kg q 8 h</p>
<p>(n=8)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">9.8 mcg/mL</p>
<p>range: 5.5 to 13.8</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">0.7 mcg/mL</p>
<p>range: 0.2 to 1</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">10 mg/kg q 8 h</p>
<p>(n=7)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">22.9 mcg/mL</p>
<p>range: 14.1 to 44.1</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">1.9 mcg/mL</p>
<p>range: 0.5 to 2.9</p>
</td>
</tr>
</tbody></table>
<p>Concentrations achieved in the cerebrospinal fluid are approximately 50% of plasma values.  Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated.</p>
<p>Renal excretion of unchanged drug is the major route of acyclovir elimination accounting for 62% to 91% of the dose.  The only major urinary metabolite detected is 9-carboxymethoxymethylguanine accounting for up to 14.1% of the dose in patients with normal renal function.</p>
<p>The half-life and total body clearance of acyclovir are dependent on renal function as shown in Table 2.</p>
<p> </p>
<p>      <span class="Bold"><span class="Emphasis">Table 2: Acyclovir Half-life and Total Body Clearance</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle">
<p class="First"> </p>
<p>Creatinine Clearance</p>
<p>(mL/min/1.73 m<span class="Sup">2</span>)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">         </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First">Total Body Clearance</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Half-Life</p>
<p>(hr)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>(mL/min/1.73 m<span class="Sup">2</span>)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>(mL/min/kg)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">&gt;80</p>
<p>50-80</p>
<p>15-50</p>
<p>0 (Anuric)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">2.5</p>
<p>3</p>
<p>3.5</p>
<p>19.5</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">327</p>
<p>248</p>
<p>190</p>
<p>29</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">5.1</p>
<p>3.9</p>
<p>3.4</p>
<p>0.5</p>
</td>
</tr>
</tbody></table>
<br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="e5f360d7-3f73-43c5-ba9f-d961dcb47e65"></a><a name="section-4.2"></a><p></p>
<h2>Special Populations<br>
</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></span></p>
<p>Acyclovir was administered at a dose of 2.5 mg/kg to 6 adult patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.  The peak and trough plasma levels during the 47 hours preceding hemodialysis were 8.5 mcg/mL and 0.7 mcg/mL, respectively.</p>
<p>Consult <span class="Bold"><span class="Emphasis"><a href="#f5059f08-4502-446b-9d1f-58da679df7f0">DOSAGE AND ADMINISTRATION</a></span></span> section for recommended adjustments in dosing based upon creatinine clearance.</p>
<p> </p>
<span class="Bold"><span class="Emphasis">Pediatrics</span></span><p>Acyclovir pharmacokinetics were determined in 16 pediatric patients with normal renal function ranging in age from 3 months to 16 years at doses of approximately 10 mg/kg and 20 mg/kg every 8 hours (Table 3).  Concentrations achieved at these regimens are similar to those in adults receiving 5 mg/kg and 10 mg/kg every 8 hours, respectively (Table 1).  Acyclovir pharmacokinetics were determined in 12 patients ranging in age from birth to 3 months at doses of 5 mg/kg, 10 mg/kg, and 15 mg/kg every 8 hours (Table 3).</p>
<p> </p>
<p>        <span class="Bold"><span class="Emphasis">Table 3: Acyclovir Pharmacokinetics in Pediatric Patients (Mean ± SD)</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>Parameter</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Birth to 3 Months of Age</p>
<p>(n=12)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">3 Months to 12 Years of Age (n=16)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">CL (mL/min/kg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">4.46 ± 1.61</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">8.44 ± 2.92</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">VDSS (L/kg)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.08 ± 0.35</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1.01 ± 0.28</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Elimination half-life</p>
<p>(hours)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>3.80 ± 1.19</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"> </p>
<p>2.36 ± 0.97</p>
</td>
</tr>
</tbody></table>
<p> </p>
<p><span class="Bold"><span class="Emphasis">Geriatrics</span></span> </p>
<p>Acyclovir plasma concentrations are higher in geriatric patients compared to younger adults, in part due to age-related changes in renal function.  Dosage reduction may be required in geriatric patients with underlying <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <span class="Bold"><span class="Emphasis"><a href="#e41047e1-c252-4fd3-82c7-fbd30bdaec9e">PRECAUTIONS,</a><span class="Italics"><a href="#e41047e1-c252-4fd3-82c7-fbd30bdaec9e"> Geriatric Use</a></span></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="df6c79cc-dd92-4164-a8a0-4386ad9feb01"></a><a name="section-4.3"></a><p></p>
<h2>Drug Interactions<br>
</h2>
<p class="First">Coadministration of probenecid with acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve.  Urinary excretion and renal clearance were correspondingly reduced.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="d0ca23fe-0b74-4006-b769-513d3f52a298"></a><a name="section-5"></a><p></p>
<h1>CLINICAL TRIALS<br>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ecd561b6-9848-44a8-ad2b-476ddd0ed0ae"></a><a name="section-5.1"></a><p></p>
<h2>Herpes Simplex <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Immuocompromised Patients<br>
</h2>
<p class="First">A multicenter trial of acyclovir at a dose of 250 mg/m<span class="Sup">2</span> every 8 hours (750 mg/m<span class="Sup">2</span>/day) for 7 days was conducted in 98 immunocompromised patients (73 adults and 25 children) with orofacial, esophageal, genital and other <span class="product-label-link" type="condition" conceptid="4018050" conceptname="Localized infection">localized infections</span> (52 treated with acyclovir and 46 with placebo).  Acyclovir decreased virus excretion, reduced <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and promoted healing of lesions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ea1c2474-cca5-40b5-8be6-f22ac5bf833a"></a><a name="section-5.2"></a><p></p>
<h2>Initial Episodes of Herpes Genitalis<br>
</h2>
<p class="First">In placebo-controlled trials, 58 patients with initial <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> were treated with intravenous acyclovir 5 mg/kg or placebo (27 patients treated with acyclovir and 31 treated with placebo) every 8 hours for 5 days.  Acyclovir decreased the duration of viral excretion, new lesion formation, and duration of <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, and promoted healing of lesions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b009b0e1-fb33-4ee9-9f43-06659246cd65"></a><a name="section-5.3"></a><p></p>
<h2>Herpes Simplex <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">Encephalitis</span><br>
</h2>
<p class="First">Sixty-two patients ages 6 months to 79 years with brain biopsy-proven herpes simplex <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">encephalitis</span> were randomized to receive either acyclovir (10 mg/kg every 8 hours) or vidarabine (15 mg/kg/day) for 10 days (28 were treated with acyclovir and 34 with vidarabine).  Overall mortality at 12 months for patients treated with acyclovir was 25% compared to 59% for patients treated with vidarabine.  The proportion of patients treated with acyclovir functioning normally or with only mild sequelae (e.g., decreased attention span) was 32% compared to 12% of patients treated with vidarabine.</p>
<p>Patients less than 30 years of age and those who had the least severe neurologic involvement at time of entry into study had the best outcome with treatment with acyclovir.  An additional controlled study performed in Europe demonstrated similar findings.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="c0974363-ee39-466e-a2d9-d1a8a75cfb79"></a><a name="section-5.4"></a><p></p>
<h2>Neonatal Herpes Simplex Virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><br>
</h2>
<p class="First">Two hundred and two infants with neonatal herpes simplex <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were randomized to receive either acyclovir 10 mg/kg every 8 hours (n=107) or vidarabine 30 mg/kg/day (n=95) for 10 days.  Outcomes are presented in Table 4.</p>
<p> </p>
<p>              <span class="Bold"><span class="Emphasis"> Table 4: Mortality at 1 Year</span></span></p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle">
<p class="First"> </p>
<p>HSV Disease Classification</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="middle"><p class="First">Treatment Group</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Acyclovir</p>
<p>(n=107)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Vidarabine</p>
<p>(n=95)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">SEM<span class="Sup">*</span> (n=85)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0/54</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">0/31</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">CNS<span class="Sup">†</span> (n=71)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5/35</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">5/36</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">DISS<span class="Sup">‡</span> (n=46)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11/18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">14/28</p></td>
</tr>
</tbody></table>
<p>* SEM refers to <span class="product-label-link" type="condition" conceptid="4018050" conceptname="Localized infection">localized infection</span> with disease limited to skin, eye, and/or mouth.</p>
<p>† CNS refers to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of the central nervous system with compatible neurologic and CSF findings.</p>
<p>‡ DISS refers to visceral organ involvement such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> with or without CNS involvement.</p>
<p> </p>
<p>Rates of neurologic sequelae at 1 year were comparable between the treatment groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="c3381327-d02c-4a87-a285-b9995cb426b6"></a><a name="section-5.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Varicella</span>-Zoster <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Immunocompromised Patients<br>
</h2>
<p class="First">A multicenter trial of acyclovir at a dose of 500 mg/m<span class="Sup">2</span> every 8 hours for 7 days was conducted in immunocompromised patients with zoster <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>).  Ninety-four (94) patients were evaluated (52 patients were treated with acyclovir and 42 with placebo).  Acyclovir was superior to placebo as measured by reductions in cutaneous dissemination and visceral dissemination.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="e079cef3-0353-4835-824e-072e3f3cfd9f"></a><a name="section-6"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="34067-9">
<a name="a14b9c89-7d71-4519-a929-516254a17578"></a><a name="section-6.1"></a><p></p>
<h2>Herpes Simplex <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Immunocompromised Patients<br>
</h2>
<p class="First">Acyclovir Sodium Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="e9c22f8d-047a-4949-9acf-3b718d7156b3"></a><a name="section-6.2"></a><p></p>
<h2>Initial Episodes of Herpes Genitalis<br>
</h2>
<p class="First">Acyclovir Sodium Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immuno-competent patients.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="a5fe7c0a-5978-4b57-b06c-c0e2d3df61d0"></a><a name="section-6.3"></a><p></p>
<h2>Herpes Simplex <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">Encephalitis</span><br>
</h2>
<p class="First">Acyclovir Sodium Injection is indicated for the treatment of herpes simplex <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">encephalitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="a12ff77e-4412-42fe-a499-fff7f31b7965"></a><a name="section-6.4"></a><p></p>
<h2>Neonatal Herpes Simplex Virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><br>
</h2>
<p class="First">Acyclovir Sodium Injection is indicated for the treatment of neonatal <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes infections</span>.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="c53b995f-303e-46c2-9d62-72734911cb54"></a><a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">Varicella</span>-Zoster <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Immunocompromised Patients<br>
</h2>
<p class="First">Acyclovir Sodium Injection is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>-zoster (<span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">shingles</span>) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in immunocompromised patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="a56a6da3-1869-450c-ada9-cb815ee59982"></a><a name="section-7"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Acyclovir Sodium Injection is contraindicated for patients who develop <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to acyclovir or valacyclovir.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ecd1b6d8-9b6c-4206-b44c-c5243744b89d"></a><a name="section-8"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Acyclovir Sodium Injection is intended for intravenous infusion only, and should not be administered topically, intramuscularly, orally, subcutaneously, or in the eye.  Intravenous infusions must be given over a period of at least 1 hour to reduce the risk of renal tubular damage (see <span class="Bold"><span class="Emphasis"><a href="#ac6f0be0-c0bd-4833-939d-074099fecbdb">PRECAUTIONS</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#f5059f08-4502-446b-9d1f-58da679df7f0">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
<p><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, in some cases resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been observed with acyclovir therapy (see <span class="Bold"><span class="Emphasis"><a href="#b32a0924-d185-4a78-a834-b352d82eb039">ADVERSE REACTIONS,</a><span class="Italics"><a href="#b32a0924-d185-4a78-a834-b352d82eb039"> Observed During Clinical Practice</a></span></span></span> and <span class="Bold"><span class="Emphasis"><a href="#ed67b088-992a-46e9-b9bb-1cba43439856">OVERDOSAGE</a></span></span>).  <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">Thrombotic thrombocytopenic purpura</span>/ <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span> (TTP/HUS), which has resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has occurred in immunocompromised patients receiving acyclovir therapy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ac6f0be0-c0bd-4833-939d-074099fecbdb"></a><a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="f1f277c1-830c-4338-81c7-faacd2e792e9"></a><a name="section-9.1"></a><p></p>
<h2>General</h2>
<p class="First">Precipitation of acyclovir crystals in renal tubules can occur if the maximum solubility of free acyclovir (2.5 mg/mL at 37°C in water) is exceeded or if the drug is administered by bolus injection.  Ensuing renal tubular damage can produce <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p>Abnormal renal function (decreased creatinine clearance) can occur as a result of acyclovir administration and depends on the state of the patient’s hydration, other treatments, and the rate of drug administration.  Concomitant use of other nephrotoxic drugs, pre-existing <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> make further <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> with acyclovir more likely.</p>
<p>Administration of acyclovir by intravenous infusion must be accompanied by adequate hydration.</p>
<p>When dosage adjustments are required, they should be based on estimated creatinine clearance (see <span class="Bold"><span class="Emphasis"><a href="#f5059f08-4502-446b-9d1f-58da679df7f0">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
<p>Approximately 1% of patients receiving intravenous acyclovir have manifested encephalopathic changes characterized by either <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.  Acyclovir should be used with caution in those patients who have underlying neurologic abnormalities and those with serious renal, hepatic, or electrolyte abnormalities, or significant <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d4264123-6f0a-4cc6-afe1-c2a43e1e3437"></a><a name="section-9.2"></a><p></p>
<h2>Drug Interactions<br>
</h2>
<p class="First">See <span class="Bold"><span class="Emphasis"><a href="#a13b4f65-814d-450a-8cdb-2e293112c2c8">CLINICAL PHARMACOLOGY,</a><span class="Italics"><a href="#a13b4f65-814d-450a-8cdb-2e293112c2c8"> Pharmacokinetics</a></span></span></span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="a4293a07-6515-4495-94c1-dfa69f8ad912"></a><a name="section-9.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility<br>
</h2>
<p class="First">The data presented below include references to peak steady-state plasma acyclovir concentrations observed in humans treated with 30 mg/kg/day (10 mg/kg every 8 hours, dosing appropriate for treatment of <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span> or herpes <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">encephalitis</span>), or 15 mg/kg/day (5 mg/kg every 8 hours, dosing appropriate for treatment of primary <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> or herpes simplex <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in immunocompromised patients).  Plasma drug concentrations in animal studies are expressed as multiples of human exposure to acyclovir at the higher and lower dosing schedules (see <span class="Bold"><span class="Emphasis"><a href="#a13b4f65-814d-450a-8cdb-2e293112c2c8">CLINICAL PHARMACOLOGY,</a> <span class="Italics"><a href="#a13b4f65-814d-450a-8cdb-2e293112c2c8">Pharmacokinetics</a></span></span></span>).</p>
<p>Acyclovir was tested in lifetime bioassays in rats and mice at single daily doses of up to 450 mg/kg administered by gavage.  There was no statistically significant difference in the incidence of tumors between treated and control animals, nor did acyclovir shorten the latency of tumors.  At 450 mg/kg/day, plasma concentrations in both the mouse and rat bioassay were lower than concentrations in humans.</p>
<p>Acyclovir was tested in 16 <span class="Italics"><span class="Emphasis">in</span></span><span class="Italics"><span class="Emphasis"> vitro</span></span> and <span class="Italics"><span class="Emphasis">in vivo</span></span> genetic toxicity assays.  Acyclovir was positive in 5 of the assays.</p>
<p>Acyclovir did not impair fertility or reproduction in mice (450 mg/kg/day, PO) or in rats (25 mg/kg/day, SC).  In the mouse study, plasma levels were the same as human levels, while in the rat study, they were 1 to 2 times human levels.  At higher doses (50 mg/kg/day, SC) in rats and rabbits (1 to 2 and 1 to 3 times human levels, respectively) implantation efficacy, but not litter size, was decreased.  In a rat peri- and post-natal study at 50 mg/kg/day, SC, there was a statistically significant decrease in group mean numbers of corpora lutea, total implantation sites, and live fetuses.</p>
<p>No testicular abnormalities were seen in dogs given 50 mg/kg/day, IV for 1 month (1 to 3 times human levels) or in dogs given 60 mg/kg/day orally for 1 year (the same as human levels).  <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">Testicular atrophy</span> and aspermatogenesis were observed in rats and dogs at higher dose levels.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e3c2afe2-fe3b-4172-8a9c-7ea9cdc28396"></a><a name="section-9.4"></a><p></p>
<h2>Pregnancy: Teratogenic Effects<br>
</h2>
<p class="First">Pregnancy Category B.</p>
<p>Acyclovir administered during organogenesis was not teratogenic in the mouse (450 mg/kg/day, PO), rabbit (50 mg/kg/day, SC and IV) or rat (50 mg/kg/day, SC).  These exposures resulted in plasma levels the same as, 4 and 9, and 1 and 2 times, respectively, human levels.</p>
<p>There are no adequate and well-controlled studies in pregnant women.  A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999.  There were 749 pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes.  The occurrence rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> approximates that found in the general population.  However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses.  Acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e787d7fd-77b6-4d0c-88fc-d38ee526532d"></a><a name="section-9.5"></a><p></p>
<h2>Nursing Mothers<br>
</h2>
<p class="First">Acyclovir concentrations have been documented in breast milk in two women following oral administration of acyclovir and ranged from 0.6 to 4.1 times corresponding plasma levels.  These concentrations would potentially expose the nursing infant to a dose of acyclovir up to 0.3 mg/kg/day.  Acyclovir should be administered to a nursing mother with caution and only when indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b6c34996-fe2e-47b6-8c12-ab9aff555bc9"></a><a name="section-9.6"></a><p></p>
<h2>Pediatric Use<br>
</h2>
<p class="First">See <span class="Bold"><span class="Emphasis"><a href="#f5059f08-4502-446b-9d1f-58da679df7f0">DOSAGE AND ADMINISTRATION</a>.</span></span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e41047e1-c252-4fd3-82c7-fbd30bdaec9e"></a><a name="section-9.7"></a><p></p>
<h2>Geriatric Use<br>
</h2>
<p class="First">Clinical studies of acyclovir did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients.  Other reported clinical experience has identified differences in the severity of CNS adverse events between elderly and younger patients (see <span class="Bold"><span class="Emphasis"><a href="#b32a0924-d185-4a78-a834-b352d82eb039">ADVERSE REACTIONS,</a><span class="Italics"><a href="#b32a0924-d185-4a78-a834-b352d82eb039"> Observed During Clinical Practice</a></span></span></span>).  In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased renal function, and of concomitant disease or other drug therapy.  This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a1f21c70-19ed-4de6-ad80-2cc24c6d7506"></a><a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The adverse reactions listed below have been observed in controlled and uncontrolled clinical trials in approximately 700 patients who received acyclovir at approximately 5 mg/kg (250 mg/m<span class="Sup">2</span>) 3 times daily, and approximately 300 patients who received approximately 10 mg/kg (500 mg/m<span class="Sup">2</span>) 3 times daily.</p>
<p>The most frequent adverse reactions reported during administration of acyclovir were <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> at the injection site in approximately 9% of the patients, and transient elevations of serum creatinine or BUN in 5% to 10% (the higher incidence occurred usually following rapid [less than 10 minutes] intravenous infusion).  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurred in approximately 7% of the patients (the majority occurring in nonhospitalized patients who received 10 mg/kg).  <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> occurred in approximately 2% of patients.  Elevation of transaminases occurred in 1% to 2% of patients.</p>
<p>The following hematologic abnormalities occurred at a frequency of less than 1%: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4189647" conceptname="Neutrophilia">neutrophilia</span>.  In addition, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> were observed.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="b32a0924-d185-4a78-a834-b352d82eb039"></a><a name="section-10.1"></a><p></p>
<h2>Observed During Clinical Practice<br>
</h2>
<p class="First">In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of Acyclovir Sodium Injection in clinical practice.  Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.  These events have been chosen for inclusion due to either their seriousness, frequency of reporting, potential causal connection to acyclovir, or a combination of these factors.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">General:</span></span></span>  <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Digestive:</span></span></span>  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, gastrointestinal distress, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Cardiovascular:</span></span></span>  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Hematologic and Lymphatic:</span></span></span>  <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">Disseminated intravascular coagulation</span>, <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>,<span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">leukocytoclastic vasculitis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Hepatobiliary Tract and Pancreas:</span></span></span>  Elevated liver function tests, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>,<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Musculoskeletal:</span></span></span>  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Nervous:</span></span></span>  <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive behavior</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, dysathria, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.  These symptoms may be marked, particularly in older adults (see PRECAUTIONS).</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Skin:</span></span></span>  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitive rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.  Severe local <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammatory reactions</span>, including tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, have occurred following infusion of acyclovir into extravascular tissues.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Special Senses:</span></span></span>  Visual abnormalities.</p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Urogenital:</span></span></span>  <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, elevated blood urea nitrogen, elevated creatinine (see WARNINGS).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ed67b088-992a-46e9-b9bb-1cba43439856"></a><a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> involving ingestions of up to 20 g have been reported.  Adverse events that have been reported in association with overdosage include <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>.  Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid.  Overdosage has been reported following bolus injections or inappropriately high doses, and in patients whose fluid and electrolyte balance were not properly monitored.  This has resulted in elevated BUN and serum creatinine, and subsequent <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.  In the event of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, the patient may benefit from hemodialysis until renal function is restored (see <span class="Bold"><span class="Emphasis"><a href="#f5059f08-4502-446b-9d1f-58da679df7f0">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f5059f08-4502-446b-9d1f-58da679df7f0"></a><a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold"><span class="Emphasis">CAUTION - RAPID OR BOLUS INTRAVENOUS INJECTION MUST BE AVOIDED</span></span> (see <span class="Bold"><span class="Emphasis"><a href="#ecd1b6d8-9b6c-4206-b44c-c5243744b89d">WARNINGS</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#ac6f0be0-c0bd-4833-939d-074099fecbdb">PRECAUTIONS</a>).</span></span></p>
<p><span class="Bold"><span class="Emphasis">INTRAMUSCULAR OR SUBCUTANEOUS INJECTION MUST BE AVOIDED (</span></span>see <span class="Bold"><span class="Emphasis"><a href="#ecd1b6d8-9b6c-4206-b44c-c5243744b89d">WARNINGS</a>).</span></span></p>
<p><span class="Bold"><span class="Emphasis">Therapy should be initiated as early as possible following onset of signs and symptoms of <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes infections</span>.</span></span> </p>
<p>A maximum dose equivalent to 20 mg/kg every 8 hours should not be exceeded for any patient.</p>
<div class="Section" data-sectionCode="34068-7">
<a name="eb459c93-2afc-4f6b-9c78-c6db5a19cec5"></a><a name="section-12.1"></a><p></p>
<h2>Dosage</h2>
<p class="First"><span class="Bold"><span class="Emphasis">HERPES SIMPLEX <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></span></span></p>
<p><span class="Italics"><span class="Emphasis">MUCOSAL AND CUTANEOUS HERPES SIMPLEX (HSV-1 and HSV-2)</span></span></p>
<span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> IN IMMUNOCOMPROMISED PATIENTS:</span></span><br><p><span class="Italics"><span class="Emphasis"><span class="Bold">Adults and Adolescents (12 years of age and older):</span></span></span></p>
<p>5 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days.</p>
<p> </p>
<span class="Italics"><span class="Emphasis"><span class="Bold">Pediatrics (Under 12 years of age):</span></span></span><br><p>10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days.</p>
<p> </p>
<span class="Italics"><span class="Emphasis">SEVERE INITIAL CLINICAL EPISODES OF HERPES GENITALIS:</span></span><br><p><span class="Italics"><span class="Emphasis"><span class="Bold">Adults and Adolescents (12 years of age and older):</span></span></span></p>
<p>5 mg/kg infused at a constant rate over 1 hour, every 8 hours for 5 days.</p>
<p> </p>
<span class="Italics"><span class="Emphasis">HERPES SIMPLEX <span class="product-label-link" type="condition" conceptid="378143" conceptname="Encephalitis">ENCEPHALITIS</span>:</span></span><br><p><span class="Italics"><span class="Emphasis"><span class="Bold">Adults and Adolescents (12 years of age and older):</span></span></span> </p>
<p>10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 10 days.</p>
<p> </p>
<span class="Italics"><span class="Emphasis"><span class="Bold">Pediatrics (3 months to 12 years of age):</span></span></span><br><p>20 mg/kg infused at a constant rate over 1 hour, every 8 hours for 10 days.</p>
<p> </p>
<span class="Italics"><span class="Emphasis"><span class="Bold">Neonatal Herpes Simplex Virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (Birth to 3 months):</span></span></span><br><p>10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 10 days.  In neonatal herpes simplex <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, doses of 15 mg/kg or 20 mg/kg (infused at a constant rate over 1 hour every 8 hours) have been used; the safety and efficacy of these doses are not known.</p>
<br><p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">VARICELLA</span>-ZOSTER <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></span></span></p>
<p><span class="Italics"><span class="Emphasis">ZOSTER IN IMMUNO­COMPROMISED PATIENTS:</span></span></p>
<p><span class="Italics"><span class="Emphasis"><span class="Bold">Adults and Adolescents (12 years of age and older:</span></span></span> </p>
<p>10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days.</p>
<p> </p>
<span class="Italics"><span class="Emphasis"><span class="Bold">Pediatrics (Under 12 years of age):</span></span></span><br><p>20 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="fb60da1c-cd34-4a24-a80c-8e119c351f3e"></a><a name="section-12.2"></a><p></p>
<h2>Obese Patients</h2>
<p class="First">Obese patients should be dosed at the recommended adult dose using Ideal Body Weight.</p>
<p><span class="Italics"><span class="Emphasis">PATIENTS WITH ACUTE OR <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">CHRONIC RENAL IMPAIRMENT</span>:</span></span> Refer to <span class="Bold"><span class="Emphasis"><a href="#f5059f08-4502-446b-9d1f-58da679df7f0">DOSAGE AND ADMINISTRATION</a></span></span> section for recommended doses, and adjust the dosing interval as indicated in Table 5.</p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">Table 5: Dosage Adjustments for Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<table width=" 438px"><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Creatinine Clearance</p>
<p>(mL/min/1.73 m<span class="Sup">2</span>)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Percent of </p>
<p>Recommended Dose</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Dosing Interval </p>
<p>(hours)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">&gt;50</p>
<p>25 to 50</p>
<p>10 to 25</p>
<p>0 to 10</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">100%</p>
<p>100%</p>
<p>100%</p>
<p>50%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">8</p>
<p>12</p>
<p>24</p>
<p>24</p>
</td>
</tr>
</tbody></table>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="a59cb487-4b43-46ea-ba0f-42f9fa66d99f"></a><a name="section-12.3"></a><p></p>
<h2>Hemodialysis</h2>
<p class="First">For patients who require dialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours.  This results in a 60% decrease in plasma concentrations following a six-hour dialysis period.  Therefore, the patient’s dosing schedule should be adjusted so that an additional dose is administered after each dialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="c26363b0-4c89-4092-bbd2-3798a7715d67"></a><a name="section-12.4"></a><p></p>
<h2>Peritoneal Dialysis<br>
</h2>
<p class="First">No supplemental dose appears to be necessary after adjustment of the dosing interval.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="bbab675d-113f-4921-afee-958fb396b831"></a><a name="section-12.5"></a><p></p>
<h2>Administration</h2>
<p class="First">The calculated dose should be further diluted in an appropriate intravenous solution at a volume selected for administration during each 1 hour infusion.  Infusion concentrations of approximately 7 mg/mL or lower are recommended.  In clinical studies, the average 70 kg adult received between 60 and 150 mL of fluid per dose.  Higher concentrations (e.g., 10 mg/mL) may produce <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> or <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> at the injection site upon inadvertent <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.  Standard, commercially available electrolyte and glucose solutions are suitable for intravenous administration; biologic or colloidal fluids (e.g., blood products, protein solutions, etc.) are not recommended.</p>
<p>Once diluted for administration, each dose should be used within 24 hours.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="f0a90911-dccb-49fd-bfc5-750431db63d1"></a><a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Acyclovir Sodium Injection is available as:</p>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Product</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC </span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="bottom">
<span class="Bold"><span class="Emphasis">Strength </span></span>     </td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">PRX302510</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-325-14 </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">500 mg per 10 mL (50 mg per mL)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Acyclovir Sodium Injection equivalent to acyclovir, in a 10 mL plastic vial, in packages of 10.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">PRX302520</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-325-24</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">1,000 mg per 20 mL (50 mg per mL)</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Acyclovir Sodium Injection equivalent to acyclovir, in a 20 mL plastic vial, in packages of 10.</p></td>
</tr>
</tbody></table>
<p>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</p>
<p>Discard unused portion.</p>
<p>This container closure is not made with natural rubber latex.</p>
<p>PREMIERPro™ Rx is a trademark of Premier, Inc., used under license.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e2e1ee25-799f-4bf8-8160-e9639774f6ca"></a><a name="section-14"></a><p></p>
<h1></h1>
<p class="First">Manufactured by:</p>
<p><span class="Bold"><span class="Emphasis">Fresenius Kabi USA, LLC</span></span></p>
<p>Lake Zurich, IL 60047 </p>
<p>451376</p>
<p>Issued: February 2014</p>
<p><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=badf347b-eeee-4239-9c74-966f262925aa&amp;name=acyclovir-sodium-injection-figure-2-prxlogo.jpg"></p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="bcb9652e-baf8-45b7-9061-5b9759e872ed"></a><a name="section-15"></a><p></p>
<h1></h1>
<span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Acyclovir 20 mL Single Dose Vial Label</span></span><p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-325-24</p>
<p>PRX302520</p>
<p><span class="Bold"><span class="Emphasis">Acyclovir Sodium Injection</span></span> </p>
<span class="Bold"><span class="Emphasis">1,000 mg per 20 mL*  </span></span><span class="Bold"><span class="Emphasis">(50 mg per mL) </span></span><p>For IV Infusion Only</p>
<p>Must Be Diluted Prior To Use</p>
<p><span class="Bold"><span class="Emphasis">20 mL</span></span> Single Dose Vial </p>
<p>Rx only</p>
<div class="Figure"><img alt="prx302520-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=badf347b-eeee-4239-9c74-966f262925aa&amp;name=acyclovir-sodium-injection-figure-3-prx302520-vial.jpg"></div>
<br><p> </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Acyclovir 20 mL Single Dose Vial Tray Label</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-325-24</p>
<p>PRX302520</p>
<p><span class="Bold"><span class="Emphasis">Acyclovir Sodium Injection</span></span> </p>
<span class="Bold"><span class="Emphasis">1,000 mg per 20 mL*  </span></span><span class="Bold"><span class="Emphasis">(50 mg per mL) </span></span><p>For IV Infusion Only</p>
<p>Must Be Diluted Prior To Use</p>
<p><span class="Bold"><span class="Emphasis">20 mL</span></span> Single Dose Vial </p>
<p>10 Vials</p>
<p>Rx only</p>
<p> </p>
<p> <img alt="prx302520-tray" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=badf347b-eeee-4239-9c74-966f262925aa&amp;name=acyclovir-sodium-injection-figure-4-prx302520-tray.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACYCLOVIR 		
					</strong><br><span class="contentTableReg">acyclovir sodium injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-325</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ACYCLOVIR SODIUM</strong> (ACYCLOVIR) </td>
<td class="formItem">ACYCLOVIR</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-325-14</td>
<td class="formItem">10  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63323-325-24</td>
<td class="formItem">10  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074930</td>
<td class="formItem">10/17/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi USA, LLC</td>
<td class="formItem"></td>
<td class="formItem">840771732</td>
<td class="formItem">MANUFACTURE(63323-325)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a4f57fc5-4f33-43c3-8468-17de38803d06</div>
<div>Set id: badf347b-eeee-4239-9c74-966f262925aa</div>
<div>Version: 1</div>
<div>Effective Time: 20140521</div>
</div>
</div> <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
